

# Product Pipeline and Clinical Roadmap

- ✓ Novel drug development platform
- ✓ Generational product development
- ✓ Psychedelic-assisted blended-therapy
- ✓ Data driven enhanced clinical outcomes through precision formulation and dosing
- ✓ Long-term shareholder value creation through strategy of deep and diverse IP asset portfolio

CLINICAL PROGRAM	INDICATION (global market)	PRECLINICAL	PHASE I	PHASE II	PHASE III
ZYL-312 High-dose psilocybin-related compound	Mood, anxiety & trauma indications (\$10B)				
ZYL-314 High-dose psilocybin-related compound	Mood, anxiety & trauma indications (10XB)				
ZYL-316 Low-dose natural psilocybin-related compound	Addition Indications (\$30B)				
ZYL-730 Technology-enabled therapy	Psychedelic-assisted therapy (\$40B)				